COMPANY PROFILE

Secura Bio

Explore full profile

Secura Bio is an integrated biopharmaceutical company

Berkeley Heights, United StatesFounded 2019Biotech & Life Sciences

Valuation $250–500M Last recorded · 2019

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Secura Bio

Secura Bio is an integrated biopharmaceutical company focused on the commercialization of oncology therapies. The company's primary product is COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) used in the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also conducting a Phase 3 study of COPIKTRA in patients with relapsed or refractory nodal T-follicular helper cell lymphoma.

Established in 2019, Secura Bio aims to bridge the gap between oncology therapies and patients. The company is headquartered in Las Vegas, Nevada, with a European office in Dublin, Ireland. Its business model is centered on acquiring, developing, and commercializing approved and late-stage development oncology assets. The company serves physicians and their patients in the oncology market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Berkeley Heights, United States
Employees: 57
Open positions: 6
Dealroom signal: 84.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Mar 2019	$55M	$220M	Athyrium Capital Management	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Secura Bio website traffic

Latest recorded traffic for Secura Bio is 3.8K monthly website visits, up 216.7% over the last three months. Secura Bio's team grew 7.5% over the past year.

Latest monthly visits3.8K 3-month web change+216.7% 1-year team growth+7.5%

Monthly website visitsMay 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Medical Science Liaison (MSL) - MidwestUnited States, Mesa · Other · Sep 6, 2026 Key Account Manager - Blue Grass RegionUnited States, Mesa · Sales · Aug 15, 2026 Market Development Manager - MidwestUnited States, Mesa · Marketing & Communication · Jun 20, 2026 Market Development Manager - SoutheastUnited States, Mesa · Marketing & Communication · Jun 20, 2026

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
FAFabentechSpecializes in the development and production of emergency treatments to combat the risks of bioterrorism and emerging infectious diseases that are priorities for public health	Lyon, France	Operational